Please login to the form below

Not currently logged in
Email:
Password:

Dermagraft

This page shows the latest Dermagraft news and features for those working in and with pharma, biotech and healthcare.

Shire pays record $350m to settle US kickback allegations

Shire pays record $350m to settle US kickback allegations

Charges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014. ... The settlement also resolves allegations that Shire and ABH promoted Dermagraft for off-label uses.

Latest news

  • Shire to file Vyvanse for binge-eating in Q3 Shire to file Vyvanse for binge-eating in Q3

    Shire's restructuring drive has already seen it divest poorly-performing foot ulcer treatment Dermagraft last year, in addition to acquiring rare disease specialist Viropharma for $4.2bn, SARcode Bioscience for

  • Shire's ADHD drug fails in depression trial Shire's ADHD drug fails in depression trial

    Nevertheless the negative result is a blow for Shire, which announced just last month it expects to face a $650m loss on the sale of its ulcer treatment Dermagraft.

  • Shire faces $650m loss on Dermagraft sale Shire faces $650m loss on Dermagraft sale

    Sells struggling foot ulcer treatment to Organogenesis. Shire has sold off its foot ulcer treatment Dermagraft to US-based Organogenesis in a loss-making deal that will see the company take ... Organogenesis now owns the rights to all Dermagraft assets,

  • Shire misses Q1 targets as Replagal sales fall Shire misses Q1 targets as Replagal sales fall

    Meanwhile, wound healing product Dermagraft fell 62 per cent to $19m thanks to a restructuring of Shire's commercial operations in regenerative medicine.

  • Eastern Europe targeted

    Dermagraft and tissue generation technologies. Acquisition. 750. Glenmark/Sanofi. GBR500 in Crohn's disease.

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    320. Shire/ Organogenesis. Divestment. Shire's sale of its Dermagraft assets acquired as part of Advanced BioHealing.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The Merck &Co divestment of Sirna is noted above but, this month, Shire announced the divestment of Dermagraft (a bioengineered skin substitution product for diabetic foot ulcers) to Organogenesis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics